Hospital
The Queen's Medical Center
The Queen's Medical Center was paid $42.67M by Medicaid between Jan 2018 and Dec 2024, across 194 billing codes. Its largest line is 99283, emergency room visit (moderate) — 40% of everything it billed.
33Billing provider infoTHE QUEEN'S MEDICAL CENTER
EWA BEACH, HI 96706
EWA BEACH, HI 96706
33aNPI1801298708assigned 09/23/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$42.67M
24GClaims373,073
24DCodes billed194
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Hawaii
Rank by total paid#6 of 18
Median peer was paid$10.94M
This provider vs. median3.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,337 | $5.31M | |
| 2019 | 51,688 | $7.77M | |
| 2020 | 34,281 | $4.63M | |
| 2021 | 53,395 | $5.53M | |
| 2022 | 64,494 | $6.22M | |
| 2023 | 66,830 | $6.60M | |
| 2024incomplete | 64,048 | $6.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 40% | 22,314 | 20,922 | $17.15M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 14,878 | 13,745 | $10.40M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 6,797 | 6,243 | $5.20M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.1% | 4,792 | 4,553 | $3.45M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.9% | 3,013 | 2,852 | $2.54M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 1,308 | 1,257 | $915K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 865 | 807 | $665K |
| 99218 | <1% | 2,595 | 1,182 | $267K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,917 | 1,198 | $264K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,421 | 1,365 | $189K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,580 | 1,561 | $169K |
| 99221 | <1% | 1,015 | 636 | $151K |
182 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 7,524 | $110K |
| 0002A | <1% | 2,227 | $89K | |
| 0001A | <1% | 2,208 | $87K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,221 | $84K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,635 | $54K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 880 | $50K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,441 | $44K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,329 | $44K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 513 | $38K |
| 87186 | <1% | 2,184 | $37K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,054 | $30K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,082 | $30K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 791 | $29K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 26 | $29K |
| 76642 | <1% | 569 | $28K | |
| 97161 | <1% | 569 | $28K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,260 | $28K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,959 | $27K |
| 0071A | <1% | 610 | $23K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,326 | $23K |
| 0072A | <1% | 566 | $22K | |
| 0004A | <1% | 531 | $21K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,381 | $20K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,149 | $20K |
| 76536 | <1% | 491 | $19K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,001 | $18K |
| 0054A | <1% | 374 | $15K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,578 | $15K |
| 76770 | <1% | 294 | $14K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 18 | $14K |
| 73562 | <1% | 1,611 | $11K | |
| 73610 | <1% | 1,393 | $11K | |
| 73630 | <1% | 1,837 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,670 | $10K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 190 | $10K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,206 | $9K |
| 73030 | <1% | 1,271 | $9K | |
| 96160 | <1% | 13,679 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 119 | $8K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 27 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,448 | $7K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,722 | $7K |
| 73110 | <1% | 714 | $7K | |
| 77066 | Tomosynthesis, mammo | <1% | 91 | $7K |
| 70496 | <1% | 66 | $6K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 16 | $6K |
| 73130 | <1% | 1,316 | $6K | |
| 0064A | <1% | 148 | $6K | |
| 87075 | <1% | 703 | $6K | |
| 71250 | <1% | 62 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,245 | $5K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 689 | $5K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 28 | $4K |
| 93975 | <1% | 45 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 55 | $4K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $3K |
| 11045 | <1% | 16 | $3K | |
| 0052A | <1% | 77 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,196 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 96 | $3K |
| 70498 | <1% | 41 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,752 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,327 | $2K |
| 20610 | <1% | 108 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 337 | $2K |
| 93017 | <1% | 89 | $2K | |
| 72100 | <1% | 207 | $2K | |
| 93246 | <1% | 131 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 191 | $2K |
| 70486 | <1% | 43 | $1K | |
| 0051A | <1% | 36 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,261 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 74 | $1K |
| 64615 | <1% | 12 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,754 | $1K |
| 92557 | <1% | 43 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,180 | $976.79 |
| 96161 | <1% | 2,744 | $877.00 | |
| 80053 | Comprehensive metabolic panel | <1% | 4,954 | $846.21 |
| 73502 | <1% | 57 | $837.17 | |
| 99205 | Prolong outpt/office vis | <1% | 75 | $831.46 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,361 | $504.26 |
| 82962 | <1% | 5,506 | $472.89 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,660 | $394.50 |
| 73080 | <1% | 88 | $386.04 | |
| 87077 | <1% | 1,068 | $358.21 | |
| 72110 | <1% | 12 | $305.73 | |
| 93976 | <1% | 230 | $289.32 | |
| 70491 | <1% | 17 | $257.96 | |
| 73090 | <1% | 64 | $203.57 | |
| 73140 | <1% | 78 | $180.64 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 852 | $145.27 |
| 87807 | <1% | 865 | $136.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,486 | $134.00 |
| 74019 | <1% | 12 | $129.57 | |
| 74018 | <1% | 13 | $127.20 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,235 | $102.62 |
| 87070 | <1% | 1,304 | $92.01 | |
| 73590 | <1% | 91 | $77.52 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,914 | $76.90 |
| 86850 | <1% | 1,042 | $74.19 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,658 | $73.44 |
| 84134 | <1% | 15 | $65.20 | |
| 81025 | <1% | 6,919 | $38.68 | |
| 87040 | <1% | 2,372 | $32.61 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 435 | $28.78 |
| 80076 | <1% | 6,790 | $23.28 | |
| 84702 | <1% | 480 | $21.84 | |
| 85610 | <1% | 3,063 | $14.97 | |
| 87088 | <1% | 1,250 | $13.66 | |
| 86140 | <1% | 1,322 | $11.43 | |
| 83735 | <1% | 766 | $9.72 | |
| 81001 | <1% | 10,118 | $9.18 | |
| 81002 | <1% | 3,320 | $7.48 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 910 | $3.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,143 | $1.34 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 2,202 | $0.00 |
| 85379 | 0% | 1,114 | $0.00 | |
| 82803 | 0% | 1,697 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 545 | $0.00 |
| 87205 | 0% | 1,248 | $0.00 | |
| 83605 | 0% | 2,707 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 949 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,849 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,418 | $0.00 |
| 96376 | 0% | 510 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 3,332 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 2,231 | $0.00 |
| 83880 | 0% | 2,171 | $0.00 | |
| 83690 | 0% | 6,818 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 2,973 | $0.00 |
| 85730 | 0% | 2,597 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 726 | $0.00 |
| 84484 | 0% | 7,381 | $0.00 | |
| 85027 | 0% | 631 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 37 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 636 | $0.00 |
| 86901 | 0% | 1,342 | $0.00 | |
| 85652 | 0% | 813 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 342 | $0.00 |
| 82330 | 0% | 502 | $0.00 | |
| 82150 | 0% | 92 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 759 | $0.00 |
| 84703 | 0% | 977 | $0.00 | |
| 80320 | 0% | 15 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 399 | $0.00 |
| 84132 | 0% | 505 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 100 | $0.00 |
| 87081 | 0% | 190 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 175 | $0.00 |
| J3490 | Unclassified drugs | 0% | 89 | $0.00 |
| 80329 | 0% | 14 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 35 | $0.00 |
| 92567 | 0% | 29 | $0.00 | |
| 88304 | 0% | 26 | $0.00 | |
| 82550 | 0% | 26 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 14 | $0.00 |
| 86900 | 0% | 1,323 | $0.00 | |
| 85014 | 0% | 1,523 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 156 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 5,886 | $0.00 |
| 82565 | 0% | 1,768 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 2,291 | $0.00 |
| 84295 | 0% | 449 | $0.00 | |
| 90715 | 0% | 313 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 932 | $0.00 |
| 84145 | 0% | 956 | $0.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 60 | $0.00 |
| 82947 | 0% | 260 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 392 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 193 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 75 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 644 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 239 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 210 | $0.00 |
| 87210 | 0% | 43 | $0.00 | |
| 29125 | 0% | 16 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 33 | $0.00 |
| 94799 | 0% | 118 | $0.00 | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 0% | 37 | $0.00 |
| 12011 | 0% | 13 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCDOWELL, PAUL (CHIEF FINANCIAL OFFICER)
Parent organizationTHE QUEEN'S MEDICAL CENTER
| Provider | Location | Paid |
|---|---|---|
| MH Mission Imaging, LLLP | Morganton, NC | $1.01M |
| MH Mission Hospital, LLLP | Asheville, NC | $581K |
| MH Mission Hospital, LLLP | Marshall, NC | $31K |
| MH Mission Hospital, LLLP | Bakersville, NC | $18K |
| The Queens Medical Center | Wahiawa, HI | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.